BI 764198: TRPC6 inhibitor
Phase 2
Indication: Focal segmental glomerulosclerosis (FSGS)
Anchored in external partnership or acquisition
This compound is under investigation, further information will be available soon.
Phase 2
Indication: Focal segmental glomerulosclerosis (FSGS)
Anchored in external partnership or acquisition
This compound is under investigation, further information will be available soon.